ClinicalTrials.gg
RecruitingNCT06398444Updated Jul 17, 2026

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

A Phase 2/3 interventional study of Lutetium[177Lu] Oxodotreotide Injection in Advanced Neuroendocrine Neoplasm, sponsored by Sinotau Pharmaceutical Group. Recruiting at 1 site in China. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Sinotau Pharmaceutical Group · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
85
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Study summary

This is a multicenter, single-arm, two-part study designed to evaluate the safety and efficacy of Lutetium [177Lu] Oxyoctreotide Injection in patients with inoperable, locally advanced or metastatic, progressive, advanced somatostatin receptor (SSTR) positive neuroendocrine neoplasms (NEN) other than grade G1/G2 gastroenteropancreatic neuroendocrine tumors (GEP-NET) and Neuroendocrine Carcinoma(NEC).

Read the detailed description

This study consists of two parts, the exploratory study (Part 1) and the pivotal study (Part 2).

In both parts, participants who signs Informed consent form (ICF) and is eligible for the study will be enrolled. Participants will receive 7.4GBq (200mCi) Lutetium [177Lu] Oxyoctreotide every 8 weeks. The objective tumor response will be assessed every 12 weeks from the time of the first dose according to RECIST 1.1 until disease progression.

02

Conditions studied

  • Advanced Neuroendocrine Neoplasm
03

In context

Lead sponsor

Sinotau Pharmaceutical Group is the lead sponsor of 17 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who have been fully informed of this study and have voluntarily signed the Form (ICF).
  2. Age ≥12 years; subjects aged 12-17 years must have a body weight ≥40kg. Age eligibility must be met at the time of signing the ICF.
  3. confirmed, unresectable locally advanced or neuroendocrine neoplasms (NENs) [excluding well-differentiated (G1 and G2) gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) and neuroendocrine carcinomas (NECs)]. The target population mainly includes:

(1)Grade 3 (G3) GEP-NET with Ki-67 index ≤ 55% (2)Other non-gastroenteropancreatic originated NEN, including pulmonary/thymic NEN, primary NEN of other sites, and NEN of unknown primary origin (3)Pheochromocytoma and paraganglioma (PPGL) Note: Histopathological specimens collected within 3 years prior to the first study drug administration are acceptable, provided that investigators confirm they can represent the pathological status at enrollment; otherwise, fresh specimens shall be collected.

4. Patients who have failed prior optimal available treatment, are intolerant to optimal available treatment, or have no access to optimal available treatment, with no restriction on the number of prior treatment lines.

Note: Optimal available treatment is determined by investigators based on individual subject conditions, including chemotherapy, targeted therapy, biologic therapy, etc.

5.Have documented disease progression within 1 year prior to the first study drug administration, and have not received any other systemic anti-tumor therapy after disease progression.

6.Have at least one at baseline per 1.1 criteria. 7. All baseline target lesions (per RECIST 1.1) must be confirmed as somatostatin receptor-positive via ⁶⁸Ga-Dotatate PET/CT.

Notes:

  1. ⁶⁸Ga-Dotatate PET/CT images obtained within 24 weeks before the first drug administration are acceptable if investigators verify they can reflect the somatostatin receptor status at enrollment;
  2. Somatostatin receptor positivity is defined as lesion uptake higher than normal liver uptake;
  3. Subjects with any target lesion confirmed somatostatin receptor-negative by ⁶⁸Ga-Dotatate PET/CT shall be excluded.

8. Have an (ECOG) performance status score of 0 or 1 at baseline.

9. Subjects of must voluntarily use effective methods throughout the treatment period and for 4 months (male) or 7 months (female) after the last dose of product, such as condoms, oral/injectable contraceptives, intrauterine devices, etc.

Exclusion criteria

Exclusion Criteria

  1. Serum creatinine > 150 μmol/L (1.7 mg/dL) or rate \< 50 mL/min (calculated by Cockcroft-Gault formula).
  2. \< 100 g/L, white blood cell count \< 2.0×10⁹/L, or count \< 100×10⁹/L.
  3. Total serum > 3 times the (ULN).
  4. Serum albumin \< 30 g/L.
  5. (ALT) or aspartate transaminase (AST) > 2.5×ULN.
  6. (INR) > 1.5 or activated partial thromboplastin time (APTT) > 1.5×ULN.
  7. Positive (HIV) antibody.
  8. Positive surface antigen (HBsAg) combined with positive HBV-DNA (≥1×10⁴ copies/mL or confirmed positive per local study center criteria); or positive virus (HCV) antibody combined with positive HCV-RNA (≥1×10³ copies/mL).
  9. Pregnant or breastfeeding females.
  10. Prior history of peptide receptor radionuclide therapy (PRRT).
  11. Subjects receiving short-acting octreotide who cannot discontinue it within 24 hours before and after administration of Lutetium-177 Oxotreotide Injection; or subjects receiving octreotide acetate microspheres who cannot stop the treatment within 6 weeks prior to the first dose of Lutetium-177 Oxotreotide Injection.

    Note: Further evaluation is required for subjects receiving other somatostatin analog (SSA) treatments.

  12. Received systemic anti-tumor therapies including targeted therapy, immunotherapy, anti-tumor traditional Chinese medicine therapy or chemotherapy within 4 weeks before the first study drug administration.
  13. Enrolled in other clinical trials and received drugs within 4 weeks prior to the first dose.
  14. Received local anti-tumor treatments such as surgery (excluding ), radical radiotherapy, hepatic arterial chemoembolization, cryoablation or radiofrequency ablation for liver within 4 weeks before the first dose.
  15. Received palliative radiotherapy for bone metastases within 2 weeks prior to the first dose.
  16. Toxicities from previous anti-tumor therapies have not recovered to Grade 1 or lower (alopecia excluded).
  17. Confirmed (excluding those stabilized for at least 24 weeks before the first administration).
  18. Uncontrolled congestive heart failure, including baseline (LVEF) \< 50%.
  19. Uncontrolled diabetes mellitus, including baseline fasting blood glucose > 2×ULN.
  20. Presence of active infections requiring intravenous antibacterial drugs or inpatient intervention.
  21. History of other confirmed malignant tumors (excluding those with complete treatment and expected no recurrence within 5 years).
  22. Known to any ingredients or of Lutetium-177 Oxotreotide Injection and octreotide acetate microspheres.
  23. to contrast-enhanced CT and MRI contrast agents due to allergic reactions or renal insufficiency.
  24. Any uncontrolled diseases, mental disorders or surgical conditions that may affect study completion (including poor treatment compliance) or make subjects ineligible for the investigational product.
  25. Based on the patient's disease characteristics, the investigator judges that alternative treatments such as chemotherapy and targeted therapy are more suitable for the patient than the study treatment, meaning the investigational product is not the optimal clinical treatment option.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    Lutetium[177Lu] Oxodotreotide Injection

    Drug: Lutetium[177Lu] Oxodotreotide Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of adverse events (AE) (Part1)

    Time frame: Until 6 months after the last dose

  2. Overall Response Rate (ORR) assessed by Independent Review Committee (IRC) (Part 2)

    Time frame: Until disease progression or death, up to 5 years

Secondary outcomes

  1. Overall Response Rate (ORR) (Part 1)

    Time frame: Until disease progression or death, up to 5 years

  2. Progression-free survival (PFS) (Part 1)

    Time frame: Until disease progression or death, up to 5 years

  3. Disease Control Rate (DCR) (Part 1)

    Time frame: Until disease progression or death, up to 5 years

  4. Duration of Overall Response (DoR) (Part 1)

    Time frame: Until disease progression or death, up to 5 years

  5. Time to Progression (TTP) (Part 1)

    Time frame: Until disease progression or death, up to 5 years

  6. PFS rate at 12 months (Part 1)

    Time frame: At 12 months after the first dose

  7. Overall Survival (OS) (Part 1)

    Time frame: Until death of any cause, up to 5 years

  8. Change From Baseline in the EORTC QLQ-C30 Questionnaire (Part 1)

    Time frame: Until disease progression or death, up to 5 years

  9. Change From Baseline in the EORTC Quality of Life Questionnaire (Part 1)

    Time frame: Until disease progression or death, up to 5 years

  10. ORR assessed by investigators (part 2)

    Time frame: Until disease progression or death, up to 5 years

  11. Progression-free survival (PFS) (Part 2)

    Time frame: Until disease progression or death, up to 5 years

  12. Disease Control Rate (DCR) (Part 2)

    Time frame: Until disease progression or death, up to 5 years

  13. Duration of Overall Response (DoR) (Part 2)

    Time frame: Until disease progression or death, up to 5 years

  14. Overall Survival (OS) (Part 2)

    Time frame: Until death of any cause, up to 5 years

  15. Change From Baseline in the EORTC QLQ-C30 Questionnaire (Part 2)

    Time frame: Until disease progression or death, up to 5 years

  16. Change From Baseline in the EORTC Quality of Life GI.NET21 Questionnaire (Part 2)

    Time frame: Until disease progression or death, up to 5 years

  17. Incidence and severity of AE (Part2)

    Time frame: Until 6 months after the last dose

  18. The proportion of subjects with a reduction of at least 50% from baseline in antihypertensive medication that was sustained for more than 6 months (evaluated only in subjects with hypertension)

    Time frame: Until disease progression or death, up to 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jun 2027, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2024
First posted
May 3, 2024
StartActual
Jun 11, 2024
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2029
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06398444
Lead sponsor
Sinotau Pharmaceutical Group
Responsible party
Sponsor
First posted
May 3, 2024
Start date
Jun 11, 2024
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Jul 17, 2026

Study contacts

Shan Zhang
Contact
zhangshan@sinotau.com
+86-010-52805710

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium-177

Start the discussion